STUDY OBJECTIVE: To (1) replicate our prior result of low cerebrospinal fluid (CSF) histamine levels in human narcolepsy in a different sample population and to (2) evaluate if histamine contents are altered in other types of hypersomnia with and without hypocretin deficiency. DESIGN: Cross sectional studies. SETTING AND PATIENTS: Sixty-seven narcolepsy subjects, 26 idiopathic hypersomnia (IHS) subjects, 16 obstructive sleep apnea syndrome (OSAS) subjects, and 73 neurological controls were included. All patients were Japanese. Diagnoses were made according to ICSD-2. RESULTS: We found significant reductions in CSF histamine levels in hypocretin deficient narcolepsy with cataplexy (mean +/- SEM; 176.0 +/- 25.8 pg/mL), hypocretin non-deficient narcolepsy with cataplexy (97.8 +/- 38.4 pg/mL), hypocretin non-deficient narcolepsy without cataplexy (113.6 +/- 16.4 pg/mL), and idiopathic hypersomnia (161.0 +/- 29.3 pg/ mL); the levels in OSAS (259.3 +/- 46.6 pg/mL) did not statistically differ from those in the controls (333.8 +/- 22.0 pg/mL). Low CSF histamine levels were mostly observed in non-medicated patients; significant reductions in histamine levels were evident in non-medicated patients with hypocretin deficient narcolepsy with cataplexy (112.1 +/- 16.3 pg/ mL) and idiopathic hypersomnia (143.3 +/- 28.8 pg/mL), while the levels in the medicated patients were in the normal range. CONCLUSION: The study confirmed reduced CSF histamine levels in hypocretin-deficient narcolepsy with cataplexy. Similar degrees of reduction were also observed in hypocretin non-deficient narcolepsy and in idiopathic hypersomnia, while those in OSAS (non central nervous system hypersomnia) were not altered. The decrease in histamine in these subjects were more specifically observed in non-medicated subjects, suggesting CSF histamine is a biomarker reflecting the degree of hypersomnia of central origin.
STUDY OBJECTIVE: To (1) replicate our prior result of low cerebrospinal fluid (CSF) histamine levels in humannarcolepsy in a different sample population and to (2) evaluate if histamine contents are altered in other types of hypersomnia with and without hypocretin deficiency. DESIGN: Cross sectional studies. SETTING AND PATIENTS: Sixty-seven narcolepsy subjects, 26 idiopathic hypersomnia (IHS) subjects, 16 obstructive sleep apnea syndrome (OSAS) subjects, and 73 neurological controls were included. All patients were Japanese. Diagnoses were made according to ICSD-2. RESULTS: We found significant reductions in CSF histamine levels in hypocretin deficient narcolepsy with cataplexy (mean +/- SEM; 176.0 +/- 25.8 pg/mL), hypocretin non-deficient narcolepsy with cataplexy (97.8 +/- 38.4 pg/mL), hypocretin non-deficient narcolepsy without cataplexy (113.6 +/- 16.4 pg/mL), and idiopathic hypersomnia (161.0 +/- 29.3 pg/ mL); the levels in OSAS (259.3 +/- 46.6 pg/mL) did not statistically differ from those in the controls (333.8 +/- 22.0 pg/mL). Low CSF histamine levels were mostly observed in non-medicated patients; significant reductions in histamine levels were evident in non-medicated patients with hypocretin deficient narcolepsy with cataplexy (112.1 +/- 16.3 pg/ mL) and idiopathic hypersomnia (143.3 +/- 28.8 pg/mL), while the levels in the medicated patients were in the normal range. CONCLUSION: The study confirmed reduced CSF histamine levels in hypocretin-deficient narcolepsy with cataplexy. Similar degrees of reduction were also observed in hypocretin non-deficient narcolepsy and in idiopathic hypersomnia, while those in OSAS (non central nervous system hypersomnia) were not altered. The decrease in histamine in these subjects were more specifically observed in non-medicated subjects, suggesting CSF histamine is a biomarker reflecting the degree of hypersomnia of central origin.
Authors: Y Sugita; S Iijima; Y Teshima; T Shimizu; N Nishimura; T Tsutsumi; H Hayashi; H Kaneda; Y Hishikawa Journal: Electroencephalogr Clin Neurophysiol Date: 1985-03
Authors: P Bonaventure; M Letavic; C Dugovic; S Wilson; L Aluisio; C Pudiak; B Lord; C Mazur; F Kamme; S Nishino; N Carruthers; T Lovenberg Journal: Biochem Pharmacol Date: 2006-11-03 Impact factor: 5.858
Authors: T Kanbayashi; Y Inoue; K Kawanishi; H Takasaki; R Aizawa; K Takahashi; Y Ogawa; M Abe; Y Hishikawa; T Shimizu Journal: J Sleep Res Date: 2003-12 Impact factor: 3.981
Authors: K A Kaplan; E L McGlinchey; A Soehner; A Gershon; L S Talbot; P Eidelman; J Gruber; A G Harvey Journal: Psychol Med Date: 2014-12-17 Impact factor: 7.723
Authors: Ritchie E Brown; Radhika Basheer; James T McKenna; Robert E Strecker; Robert W McCarley Journal: Physiol Rev Date: 2012-07 Impact factor: 37.312